The University of Southampton
University of Southampton Institutional Repository

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer

Rao, S., Cunningham, D., de Gramont, A., Scheithauer, W., Smakal, M., Humblet, Y., Kourteva, G., Iveson, T., Andre, T., Dostalova, J., Illes, A., Belly, R., Perez-Ruixo, J.J., Park, Y.C. and Palmer, P.A. (2004) Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer Journal of Clinical Oncology, 22, (19), pp. 3950-3957. (doi:10.1200/JCO.2004.10.037).

Record type: Article


Purpose: To determine whether R115777 improves survival in patients with refractory advanced colorectal cancer (CRC) in a multicenter, double-blind, prospective randomized study.
Patients and Methods: Three hundred sixty-eight patients were randomly assigned to R115777 (300 mg twice daily) orally for 21 days every 28 days or placebo in a 2:1 ratio. All patients received best supportive care. The primary end point was overall survival; secondary end points were progression free survival, tumor response, toxicity, and quality of life.
Results: The two treatment groups were well balanced for baseline demographics, including previous chemotherapy for advanced CRC. The median overall survival for R115777 was 174 days (95% CI, 157 to 198 days), and 185 days (95% CI, 158 to 238 days) for those patients receiving placebo (P = .376). One patient achieved a partial response in the R115777 arm. Stable disease (> 3 months) was observed in 24.3% patients in the R115777 group compared to 12.8% in the placebo arm. This did not translate into a statistically significant increase in progression-free survival. Overall, treatment was well tolerated. There was an increased incidence of reversible myelosuppression (neutropenia, thrombocytopenia), rash, and grade 1 to 2 diarrhea in the R115777 arm. There was no statistically significant difference in quality of life between arms.
Conclusion: Single agent R115777, given at this dose and schedule, has an acceptable toxicity profile, but does not improve overall survival compared to best supportive care alone in refractory advanced CRC.

PDF 26551.pdf - Version of Record
Restricted to Repository staff only
Download (1MB)

More information

Published date: 2004


Local EPrints ID: 26551
ISSN: 1527-7755
PURE UUID: c72827ce-2b92-4372-9e65-64ec324cd130

Catalogue record

Date deposited: 20 Apr 2006
Last modified: 17 Jul 2017 16:07

Export record



Author: S. Rao
Author: D. Cunningham
Author: A. de Gramont
Author: W. Scheithauer
Author: M. Smakal
Author: Y. Humblet
Author: G. Kourteva
Author: T. Iveson
Author: T. Andre
Author: J. Dostalova
Author: A. Illes
Author: R. Belly
Author: J.J. Perez-Ruixo
Author: Y.C. Park
Author: P.A. Palmer

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.